^
    Back
    Association details:
    Biomarker:TNFRSF8 positive
    Cancer:Peripheral T-cell Lymphoma
    Regimen: (etoposide IV + carboplatin + Adcetris (brentuximab vedotin) + ifosfamide)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Eur J Haematol
    Title:

    Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma

    Published date:
    12/15/2020
    Excerpt:
    We aimed at assessing efficacy of ifosfamide, carboplatin, etoposide (ICE) regimen, a known therapeutic option, to which we added brentuximab-vedotin (BV)....Fourteen patients received BV-ICE...all were CD30 positive....Overall response was seen in four (29%) patients, and complete response (CR) in two (14%)….Two-year progression-free and overall survival were 14% and 17.5%.
    DOI:
    10.1111/ejh.13568